Kura Oncology KURA Other long-term liabilities
Other long-term liabilities at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's other long-term liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Kura Oncology's other long-term liabilities?
- Kura Oncology (KURA) reported other long-term liabilities of $204K in Q1 2026.
- How has Kura Oncology's other long-term liabilities changed year-over-year?
- Kura Oncology's other long-term liabilities decreased by 21.2% year-over-year, from $259K to $204K.
- What is the long-term trend for Kura Oncology's other long-term liabilities?
- Over 2 years (2023 to 2025), Kura Oncology's other long-term liabilities has grown at a 175.9% compound annual growth rate (CAGR), from $137K to $1.04M.